Advice
in the absence of a submission from the holder of the marketing authorisation:
eculizumab 300mg (Soliris®) is not recommended for use within NHSScotland.
Indication under review: Treatment of adults with neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice622KB (PDF)
Medicine details
- Medicine name:
- eculizumab (Soliris)
- SMC ID:
- SMC2456
- Indication:
For treatment of adults with neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease.
- Pharmaceutical company
- Alexion Pharma UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 17 January 2022